ABSI · CIK 0001672688
Absci Corp
What Absci Corp owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Absci Corp - Profile
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
- Listed on
- Nasdaq
- Employees
- 140stated 2025
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Absci Corp's own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from Absci Corporation Form 10-K for fiscal year 2025 and Absci Corporation Form 10-Q for the quarter ended 30 June 2026, not taken from any single article.
Share price
ABSI
Description
Absci Corporation is a clinical-stage biopharmaceutical company in Vancouver, Washington that designs antibody therapeutics with generative AI. Its Integrated Drug Creation platform pairs Origin-1, a de novo antibody design model, with wet lab validation in a lab-in-a-loop cycle. Lead candidate ABS-201, an anti-prolactin receptor antibody, is in the HEADLINE Phase 1/2a trial for androgenetic alopecia, with a Phase 2 trial in endometriosis planned for the fourth quarter of 2026. Absci has no approved product and is loss-making. Its only revenue is partner program fees from drug creation agreements: $2.8 million in 2025, down from $4.5 million in 2024, with three partners supplying 95% of it. The 2025 net loss was $115.2 million on operating expenses of $123.1 million, and accumulated deficit reached $624.8 million. Revenue fell to $0.5 million in the first half of 2026 against a $62.8 million net loss. Cash, cash equivalents and marketable securities were $201.1 million at 30 June 2026. Absci employed 140 people at 31 December 2025.
Who owns Absci Corp.
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 160 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
160 managers reported a position, together holding 126.2m shares, or 80.9% of the company. The 40 largest are listed. Percentages are of the 155.9m shares outstanding at 30 Apr 2026, the count in force when this quarter was measured rather than the count today.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 22 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 00091E109, held by amd, ameriprise, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, geode, goldman-sachs, invesco, jpmorgan, metlife, morgan-stanley, northern-trust, pnc, prudential-financial, raymond-james, state-street, truist, us-bancorp, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.